Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The product will be manufactured at Lupin’s facility in Pithampur, India
This has further strengthened its manufacturing presence in the United States of America
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
Subscribe To Our Newsletter & Stay Updated
